01698nas a2200325   4500000000100000008004100001260001300042653001200055653003700067653003300104653003000137653001100167653001200178653002400190653001500214653001300229653000900242100001500251700001400266700001500280700001400295700001400309245024000323856005900563300001100622490000700633050003200640520068600672022001401358       1991                            d  c1991 Jun10aDapsone10aDemocratic Republic of the Congo10aDrug Administration Schedule10aDrug Therapy, Combination10aHumans10aleprosy10aProspective Studies10aRecurrence10aRifampin10aSkin1 aPattyn S R1 aGroenen G1 aJanssens L1 aKuykens L1 aMputu L B00aA controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone. The Collaborative Study Group for the Treatment of Leprosy in Zaire.  uhttp://leprev.ilsl.br/pdfs/1991/v62n2/pdf/v62n2a09.pdf  a179-850 v62  aInfolep Library - available3 a<p>The cure rates of two treatment regimens in PB leprosy were compared in a prospective randomized trial: treatment U consisting of a single dose of rifampicin 40 mg/K bodyweight, and treatment A of rifampicin 1500 mg in a single dose, followed by one year of daily dapsone 100 mg. In patients with a BI = 0, the cure rates evaluated on the basis of histopathology of skin biopsies, were identical for the two regimens but in patients with a BI = 1, cure and relapse rates were unacceptable. For this reason and particularly the need to separate patients on the basis of the BI in skin biopsies, the single dose regimen does not appear to be suited for wide-scale application.</p>  a0305-7518